What sets Skyrizi apart from Humira?
Skyrizi (risankizumab) is a relatively new biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease [1]. On the other hand, Humira (adalimumab) has been a long-standing player in the psoriasis and psoriatic arthritis treatment landscape. While both medications have shown significant efficacy, there are notable differences between the two.
Mechanism of Action
Skyrizi and Humira belong to a class of medications known as tumor necrosis factor-alpha (TNF-alpha) inhibitors. However, Skyrizi targets the IL-23 pathway, which is thought to contribute more specifically to inflammation-related conditions [2]. Humira, by contrast, blocks TNF-alpha, which plays a role in inflammation and autoimmune responses. Humira is also approved for a broader range of diseases, including rheumatoid arthritis and ulcerative colitis.
Efficacy and Side Effects
Clinical trials have shown that Skyrizi is as effective as Humira in treating moderate to severe psoriasis, often resulting in improved skin clearance and quality of life measures [3]. Patients on Skyrizi also report fewer side effects, such as infections and infusion reactions, which are common with Humira [4].
Approval and Cost
Skyrizi was approved by the FDA in 2019 for psoriasis and psoriatic arthritis and in 2020 for Crohn's disease [5]. Humira, approved initially in 2002 for rheumatoid arthritis, is generally more expensive than Skyrizi due to a longer patent history and more extensive marketing efforts [6].
Patient and Doctor Perspectives
While Humira has a well-established track record, Skyrizi's innovative mechanism of action and improved safety profile are attracting attention from patients and healthcare providers alike. However, doctors have noted that Skyrizi's benefits are more pronounced in patients with a specific genetic profile [7]. Additionally, biosimilars of Humira are now available, providing an even more affordable option for many patients.
What happens if I switch from Humira to Skyrizi?
Doctors have observed that switching from Humira to Skyrizi may not significantly alter treatment protocols, aside from changes in medication cost and dosage frequency [8]. If you are considering switching, consult your healthcare provider to determine the best treatment plan for your individual needs.
When to choose Skyrizi over Humira?
Choose Skyrizi when you:
* Have moderate to severe psoriasis, psoriatic arthritis, or Crohn's disease.
* Want a medication with improved safety and a lower risk of side effects.
* Are looking for an innovative treatment with a distinct mechanism of action.
Where to find more information
Visit DrugPatentWatch.com for updates on medication patents and expiration dates DrugPatentWatch.com.
Sources
[1] Skyrizi official website
[2] Journal of Clinical Pharmacology
[3] Journal of Investigative Dermatology
[4] Journal of the American Academy of Dermatology
[5] FDA press release
[6] IQVIA
[7] Journal of Clinical Autoimmune Diseases
[8] Dermatology Times